Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Conduit Pharmaceuticals Inc (NASDAQ: CDT) closed at $3.23 down -18.02% from its previous closing price of $3.94. In other words, the price has decreased by -$18.02 from its previous closing price. On the day, 1.24 million shares were traded.
Ratios:
For a deeper understanding of Conduit Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.31. In the meantime, Its Debt-to-Equity ratio is 1.07 whereas as Long-Term Debt/Eq ratio is at 0.03.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 03 ’24 when Nirland Ltd sold 1,500,000 shares for $0.10 per share. The transaction valued at 156,450 led to the insider holds 8,400,000 shares of the business.
Nirland Ltd sold 1,368,991 shares of CDT for $140,458 on Oct 04 ’24. The 10% Owner now owns 7,031,009 shares after completing the transaction at $0.10 per share. On Oct 07 ’24, another insider, Nirland Ltd, who serves as the 10% Owner of the company, sold 939,009 shares for $0.10 each. As a result, the insider received 96,530 and left with 6,092,000 shares of the company.
Stock Price History:
Over the past 52 weeks, CDT has reached a high of $4680.00, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is -60.93%, while the 200-Day Moving Average is calculated to be -96.57%.
Shares Statistics:
A total of 0.63M shares are outstanding, with a floating share count of 0.34M. Insiders hold about 54.39% of the company’s shares, while institutions hold 4.54% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
